Imetelstat治疗较低危骨髓增生异常肿瘤患者克隆负荷的调节
本文基于III期IMerge试验的探索性分析,评估端粒酶抑制剂Imetelstat对较低危MDS患者克隆负荷的影响。结果显示Imetelstat组多基因变异等位基因频率持续降低幅度大于安慰剂组,且与红细胞输血非依赖持续时间正相关;部分患者达细胞遗传学反应或特定基因克隆负荷降低≥50%时,≥1年红细胞输血非依赖率更高。
要点
- Imetelstat组多基因VAF持续降低优于安慰剂,且与RBC-TI持续时间正相关。
- 细胞遗传学反应患者中70%达≥1年RBC-TI。
- SF3B1、TET2、DNMT3A或ASXL1克隆负荷降低≥50%者≥1年RBC-TI率更高。
核心结论
- Imetelstat可靶向克隆祖细胞并可能改变LR-MDS生物学特征。
研究设计与样本
- III期IMerge试验(NCT02598661)的探索性分析,纳入非del(5q)、红细胞输血依赖、对ESA复发/难治或不适合的LR-MDS患者。
主要发现
- Imetelstat组多基因VAF持续降低幅度大于安慰剂组,且与RBC-TI持续时间正相关。
- 细胞遗传学反应患者中70%达≥1年RBC-TI。
- SF3B1 VAF降低≥50%者≥1年RBC-TI率58% vs 7%,TET2为90% vs 9%,DNMT3A为100% vs 13%,ASXL1为50% vs 0%。
- 骨髓环状铁粒幼红细胞减少≥50%者≥1年RBC-TI率46% vs 0%。
- ≥1年RBC-TI患者中60%有端粒酶活性/hTERT RNA降低≥50%。
关键数值与推荐
- SF3B1 VAF降低≥50%者≥1年RBC-TI率58% vs 7%。
- TET2 VAF降低≥50%者≥1年RBC-TI率90% vs 9%。
- DNMT3A VAF降低≥50%者≥1年RBC-TI率100% vs 13%。
- ASXL1 VAF降低≥50%者≥1年RBC-TI率50% vs 0%。
- 骨髓环状铁粒幼红细胞减少≥50%者≥1年RBC-TI率46% vs 0%。
临床怎么用
- Imetelstat可能通过靶向克隆祖细胞改变LR-MDS疾病生物学,克隆负荷降低或可预测RBC-TI持续时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Existing treatments for lower-risk myelodysplastic syndromes/neoplasms (LR-MDS) focus on symptom relief. Until recently, altering the disease course was rarely considered a therapeutic objective. The first-in-class, direct, competitive telomerase inhibitor, imetelstat, demonstrated significantly higher rates of red blood cell (RBC) transfusion independence (TI) versus placebo in patients with non-del(5q), RBC transfusion-dependent LR-MDS who were relapsed/refractory to or ineligible for erythropoiesis-stimulating agents in the Phase 3 IMerge study (NCT02598661). In this exploratory analysis of IMerge, patients treated with imetelstat had greater sustained reductions in variant allele frequency of multiple mutations versus placebo recipients, which was positively associated with RBC-TI duration. Subsequent analyses showed that 70% of patients with a cytogenetic response with imetelstat achieved ≥1-year RBC-TI. Additionally, higher rates of ≥1-year RBC-TI were observed in patients with maximum variant allele frequency reduction of ≥50% in SF3B1 (58% vs. 7%), TET2 (90% vs. 9%), DNMT3A (100% vs. 13%), or ASXL1 (50% vs. 0%) and patients with ≥50% bone marrow ring sideroblast reduction (46% vs. 0%) versus patients who did not. Lastly, 60% of patients with ≥1-year RBC-TI had ≥50% reduction in telomerase activity/human telomerase reverse transcriptase RNA. These results suggest that imetelstat targets clonal progenitor cells and may modify LR-MDS biology.
引用
- Santini V, Zeidan AM, Van Eygen K, et al. Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat. Leukemia. 2026. PMID: 41526614. doi:10.1038/s41375-025-02831-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。